Ind-Swift Laboratories is currently trading at Rs. 17.35, up by 0.80 points or 4.83% from its previous closing of Rs. 16.55 on the BSE.
The scrip opened at Rs. 17.00 and has touched a high and low of Rs. 17.35 and Rs. 16.75 respectively. So far 900 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 49.00 on 18-Mar-2019 and a 52 week low of Rs. 15.25 on 06-Mar-2020.
Last one week high and low of the scrip stood at Rs. 17.35 and Rs. 15.85 respectively. The current market cap of the company is Rs. 97.79 crore.
The promoters holding in the company stood at 52.16%, while Institutions and Non-Institutions held 0.46% and 47.37% respectively.
United States Food and Drug Administration (USFDA) has completed inspection at Ind-Swift Laboratories’ API manufacturing facility at Derabassi (Punjab), near Chandigarh, India, which was conducted from March 9, 2020 to March 13, 2020. The USFDA has cleared this inspection without any 483 observation.
The Derabassi API manufacturing facility of the company, which has 22 Independent manufacturing blocks, is one of the largest manufacturing facility of Northern India, with annual manufacturing capacity of 695 tonnes per annum.
Ind-Swift Laboratories is engaged in the manufacture of Active Pharmaceutical Ingredients (API). The product range of the company includes Macrolide antibiotics, Cardiovascular, Anti histamine, Anti diabetic, Analgesic, Aromatase inhibtors, Anti depressant,Alcohol absistence, etc.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |